PDCD1 and neoplasm: One primary mechanism underlying secondary resistance to anti-PD-1 therapy involves the downregulation of antigen presentation on the tumor cell surface, which can be mediated by the upregulation of the interferon γ signaling pathway after exposure to checkpoint inhibitors [122,123,124,125].